Skip to content

Application of Oxalidine in Gynecological Endoscopic Surgery

Application of Oxalidine in Gynecological Endoscopic Surgery: A Randomized Controlled, Double Blind, Non-Inferior Single Center Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114261
Enrollment
Unknown
Registered
2025-12-09
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain

Interventions

Sufentanil group:Use sufentanil as an analgesic during surgery
Oliceridine group:Use Oliceridine as an analgesic during surgery

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Selecting patients diagnosed with uterine fibroids or ovarian cysts before surgery for gynecological laparoscopic surgery 2.Expected surgery time exceeds 1 hour 3.American Society of Anesthesiologists (ASA) classification I-II 4.Age range: 18-65 years old

Exclusion criteria

Exclusion criteria: 1. Body weight > 75 kg 2. Presence of severe organic pathology (coronary heart disease, bronchial asthma, severe hypertension, significant haematological dysfunction, marked abnormalities in hepatic or renal function, or electrolyte imbalance) 3. Atrioventricular block, bradycardia (HR < 50 beats per minute), hypotension (SBP < 90 mmHg) 4. History of neurological disorders; chronic pain; substance dependence or alcohol abuse; prolonged opioid use history 5. History of opioid allergy 6. Patients with delayed gastric emptying or gastroparesis; impaired intestinal motility or intestinal obstruction 7. Participants enrolled in other clinical trials 8. Patients with other conditions deemed ineligible by the investigator

Design outcomes

Primary

MeasureTime frame
Postoperative NRS scores;

Secondary

MeasureTime frame
Incidence of QT interval prolongation;

Countries

China

Contacts

Public ContactWang Sheng

The First Affiliated Hospital of University of Science and Technology of China

iamsheng2020@ustc.edu.cn+86 191 5600 7726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026